These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19584228)

  • 1. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
    Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
    J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.
    Ji X; Wang H; Zhu J; Zhu L; Pan H; Li W; Zhou Y; Cong Z; Yan F; Chen S
    Int J Cancer; 2014 Aug; 135(3):574-84. PubMed ID: 24374745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
    Rapisarda A; Zalek J; Hollingshead M; Braunschweig T; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Hewitt SM; Shoemaker RH; Melillo G
    Cancer Res; 2004 Oct; 64(19):6845-8. PubMed ID: 15466170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis.
    Nam SY; Ko YS; Jung J; Yoon J; Kim YH; Choi YJ; Park JW; Chang MS; Kim WH; Lee BL
    Br J Cancer; 2011 Jan; 104(1):166-74. PubMed ID: 21119667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
    Ramezani S; Vousooghi N; Ramezani Kapourchali F; Yousefzadeh-Chabok S; Reihanian Z; Alizadeh AM; Khodayari S; Khodayari H
    Life Sci; 2019 Dec; 239():116880. PubMed ID: 31678282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemia regression by vascular disruption and antiangiogenic therapy.
    Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
    Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
    Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
    Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
    Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
    Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
    Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
    Rapisarda A; Uranchimeg B; Scudiero DA; Selby M; Sausville EA; Shoemaker RH; Melillo G
    Cancer Res; 2002 Aug; 62(15):4316-24. PubMed ID: 12154035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
    Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
    Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
    Terzuoli E; Donnini S; Giachetti A; Iñiguez MA; Fresno M; Melillo G; Ziche M
    Clin Cancer Res; 2010 Aug; 16(16):4207-16. PubMed ID: 20682710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
    Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
    Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.
    Kim YJ; Lee HJ; Kim TM; Eisinger-Mathason TS; Zhang AY; Schmidt B; Karl DL; Nakazawa MS; Park PJ; Simon MC; Yoon SS
    Int J Cancer; 2013 Jan; 132(1):29-41. PubMed ID: 22684860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
    Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
    Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis.
    Yang T; Yao Q; Cao F; Liu Q; Liu B; Wang XH
    Int J Nanomedicine; 2016; 11():6679-6692. PubMed ID: 27994464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.